Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
guadecitabine
- Development stage
- Phase 3
- Lead developer
- Astex Pharmaceuticals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
Guadecitabine is a next-generation small molecule hypomethylating agent and dinucleotide antimetabolite composed of decitabine linked via a phosphodiester bond to deoxyguanosine. It acts as an inhibitor of DNA cytosine 5-methyltransferase 1 (DNMT1), leading to the reversal of aberrant DNA methylation and reactivation of silenced tumor suppressor genes. Guadecitabine was developed primarily for hematological malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with additional investigation in various solid tumors. It was designed for subcutaneous administration to provide prolonged exposure compared to decitabine[2][5][6][7].
- Other names
- decitabine deoxyguanosinedecitabine deoxyguanosine dinucleotideguadecitabine sodium
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on guadecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on guadecitabine.